Immunoglobulins in Sepsis

  • G. Berlot
  • C. M. Vassallo
  • N. Busetto
Conference paper


For decades, intravenously administered immunoglobulin preparations (IvIg) have been extensively used in different categories of critical diseases, including sepsis, polyneuritis of different origins and myasthenia gravis (MG). From this short list, it is evident that IvIg have been administered either to boost or to downregulate patients’ immunologic response. These apparently opposing indications are a result of their pleiotropic effects on the immune system, which include: (a) immune response augmentation through an increase in opsonisation and phagocytosis and complement system activation; and (b) reduced inflammatory response via decreased production of tumour necrosis factor-α (TNF-α) and other inflammatory mediators and increased release of soluble receptors for a number of cytokines [1, 2]. This dual effect of IvIg makes them a valuable therapeutic tool either in the phase of full-blown inflammation or in the subsequent compensatory anti-inflammatory response syndrome (CARS) [3], which is associated with an overall reduction of the immunologic response [4].


Septic Shock Severe Sepsis Innate Immune System Septic Patient Toxic Shock Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Spath PJ (1999) Structure and function of immunoglobulins. Sepsis 3: 197–218CrossRefGoogle Scholar
  2. 2.
    Werdan K (1999) Supplemental immune globulins in sepsis Clin Chem Lab Med 37: 341–349Google Scholar
  3. 3.
    Bone RC (1996) Sir Isaac Newton, Sepsis, SIRS and CARS. Crit Care Med 24: 1125–1136PubMedCrossRefGoogle Scholar
  4. 4.
    Hotchkiss RS, Karl IE (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348: 138–150PubMedCrossRefGoogle Scholar
  5. 5.
    Deans KJ, Haley M, Natanson C et al (2005) Novel therapies for sepsis: a review. J Trauma 58: 867–874PubMedCrossRefGoogle Scholar
  6. 6.
    Cohen J (2002) The immunopathogenesis of sepsis. Nature 420: 885–891PubMedCrossRefGoogle Scholar
  7. 7.
    Medzhitov R, Janeway C (2000) Advances in immunology: innate immunity. N Engl J Med 343: 337–344CrossRefGoogle Scholar
  8. 8.
    Werdan K (2001) Intravenous immunoglobulin for prophylaxis and therapy of sepsis. Curr Opin Crit Care 7: 354–361PubMedCrossRefGoogle Scholar
  9. 9.
    Werdan K (1999) Immunoglobulins in sepsis: therapeutic use of immunoglobulins. Sepsis 3: 239–346CrossRefGoogle Scholar
  10. 10.
    Abraham E (1999) Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med 25: 556–566PubMedCrossRefGoogle Scholar
  11. 11.
    van der Poll T, van Deventer SJ (1999) Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am 13: 413–426PubMedCrossRefGoogle Scholar
  12. 12.
    Breedveld F (2000) Therapeutic monoclonal antibodies. Lancet 355: 735–740PubMedCrossRefGoogle Scholar
  13. 13.
    Scott DL, Kingsley GH (2006) Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 355: 704–712PubMedCrossRefGoogle Scholar
  14. 14.
    Little D, Regan M, Keane M (1993) Perioperative immune modulation. Surgery 114: 87–91PubMedGoogle Scholar
  15. 15.
    Safdar A, Armstromg D (2001) Infectious morbidity in critically ill patients with cancer. Crit Care Clin 17: 531–550PubMedCrossRefGoogle Scholar
  16. 16.
    Kalb TH, Lorin S (2002) Infection in the chronic critically ill: unique risk profile in a newly defined population. Crit Care Clin 18: 529–552PubMedCrossRefGoogle Scholar
  17. 17.
    Jenson HB, Pollock BH (1998) The role of intravenous immunoglobulin for the prevention and treatment of neonatal sepsis. Semin Perinatol 22: 50–63PubMedCrossRefGoogle Scholar
  18. 18.
    Shenoi A, Nagesh NK, Maiya PP et al (1999) Multicenter randomized placebo controlled trial of therapy with intravenous immunoglobulin in decreasing mortal¬ity due to neonatal sepsis. Indian Pediatr 36: 1113–1138PubMedGoogle Scholar
  19. 19.
    Sablotzki A, Friedrich I, Holzheimer RG et al (1999) Prophylactic use of immunoglobulins in cardiac surgery. Sepsis 3: 247–253CrossRefGoogle Scholar
  20. 20.
    Pilz G, Kreuzer E, Kaab S et al (1994) Early sepsis treatment with immunoglobulins after cardiac surgery in score-identified high risk patients. Chest 105: 76–82PubMedCrossRefGoogle Scholar
  21. 21.
    Pilz G, Appel R, Kreuzer E, Werdan K (1997) Comparison of early IgM-enriched immunoglobulin vs polyvalent IgG administration in score-identified post cardiac surgical patients at high risk for sepsis. Chest 111: 419–426PubMedCrossRefGoogle Scholar
  22. 22.
    Rankin JS, Glower DD, Teichmann TL et al (2006) Immunotherapy for refractory pulmonary infection after adult cardiac surgery: immune dysregulation syndrome. J Heart Valve Dis 14: 783–791Google Scholar
  23. 23.
    Buda S, Riefolo A, Biscione et al (2005) Clinical experience with polyclonal IgM- enriched immunoglobulins in a group of patients affected by sepsis after cardiac surgery. J Cardiovas Vasc Anesth 19: 440–445CrossRefGoogle Scholar
  24. 24.
    Dellinger RP, Levy MM, Carlet JM et al (2008) Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intens Care Med 34: 17–60CrossRefGoogle Scholar
  25. 25.
    Alejandra MM, Lansang MA, Dans LF et al (2002) Intravenous immunoglobulin for treating sepsis an septic shock. Cochrane Database Syst Rev 1:CD001090Google Scholar
  26. 26.
    Turgeon AF, Hutton B, Fergusson DA et al (2007) Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med 146: 193–203PubMedGoogle Scholar
  27. 27.
    Pildal J, Goetzshe PC (2004) Polyclonal immunoglobulins for the treatment of bacterial sepsis: a systematic review. Clin Infect Dis 39: 38–46PubMedCrossRefGoogle Scholar
  28. 28.
    Norrby-Teglund A, Ihendyane N, Daremberg J (2003) Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections. Scand J Infect Dis 35: 683–689PubMedCrossRefGoogle Scholar
  29. 29.
    Daremberg J, Ihendyane N, Sjolin J et al (2003) Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double- blind, placebo-controlled trial. Clin Infect Dis 37: 333–340CrossRefGoogle Scholar
  30. 30.
    Neilson AR, Burchardi H, Schneider H (2005) Cost-effectiveness of immunoglobulin M-enriched immunoglobulin ( Pentaglobin) in the treatment of severe sepsis and septic shock. J Crit Care 20: 239–250Google Scholar
  31. 31.
    Norby-Teglund A, Haque KN, Hammarstrom L et al (2006) Intravenous poly- clonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis. J Intern Med 260: 509–516CrossRefGoogle Scholar
  32. 32.
    Maury E, Blanchard HS, Chauvin P et al (2003) Circulating endotoxin and antiendotoxin antibodies during severe sepsis and septic shock. J Crit Care 2003: 115–120Google Scholar
  33. 33.
    Rodriguez A, Rello J, Neira J et al (2005) Effects of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock 23: 298–304PubMedCrossRefGoogle Scholar
  34. 34.
    Dominioni L, Dionigi R, Zanello M et al (1991) Effects of high-dose IgG on survival of surgical patients with sepsis score of 20 or greater. Arch Surg 126: 236–240PubMedCrossRefGoogle Scholar
  35. 35.
    Cafiero F, Gipponi M, Bonalimi U et al (1992) Prophylaxis of infection with intravenous immunoglobulins plus antibiotics for patients at risk for sepsis undergoing surgery for colorectal cancer: results of a randomized, multicentre clinical trial. Surgery 112: 24–31PubMedGoogle Scholar
  36. 36.
    Schedel I, Dreikhausen U, Newtig B et al (1991) Treatment of gram negative septic shock with immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med 19: 1104–1113PubMedCrossRefGoogle Scholar
  37. 37.
    Hentrich M,Fehnle K, Ostermann H et al (2006) IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, con¬trolled multiple-center trial. Crit Care Med 1319–1325Google Scholar
  38. 38.
    Tugrul S, Ozcan PE, Akinci O et al (2002) The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis (ISRCTN28863830). Crit Care 30: 357–362CrossRefGoogle Scholar
  39. 39.
    Berlot G, Dimastromatteo G (2004) Impiego delle immunoglobuline arricchite con IgM e IgA nel trattamento della sepsi severa e dello shock settico. Esperienza clinica. Minerva Anestesiol 70: 739–745Google Scholar

Copyright information

© Springer-Verlag Italia 2011

Authors and Affiliations

  • G. Berlot
  • C. M. Vassallo
  • N. Busetto

There are no affiliations available

Personalised recommendations